Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Repeat-dosing toxicology studies of ATL-1103 are completed in mice and primates

Oct. 14, 2009

Recent clinical data show advantages of alogliptin plus pioglitazone combination

Oct. 14, 2009

Liraglutide shows advantages over glimepiride in LEAD-2 type 2 diabetes study

Oct. 14, 2009

Dalcetrapib effective and well tolerated in diabetes and metabolic syndrome patients

Oct. 14, 2009

Data show Afresa efficacy in diabetes with no significant effects on lung function

Oct. 14, 2009

Novel TpoR agonists in early development at Shanghai Hengrui

Oct. 13, 2009

New compounds for the treatment of obesity claimed by University of Strathclyde

Oct. 13, 2009

Pooled analysis shows saxagliptin beneficial in elderly type 2 diabetes patients

Oct. 13, 2009

Benefit of phentermine/topiramate seen in type 2 diabetes patients in phase II trial

Oct. 13, 2009

FDA approves Daiichi Sankyo's sNDA for Welchol in pediatric patients with heFH

Oct. 9, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...